Valeo Pharma (TSE:VPH) Shares Down 16.1% on Disappointing Earnings

Shares of Valeo Pharma Inc. (TSE:VPH) fell 16.1% during trading on Friday following a dissappointing earnings announcement. The stock traded as low as C$0.13 and last traded at C$0.13. 171,638 shares traded hands during mid-day trading, an increase of 152% from the average session volume of 68,209 shares. The stock had previously closed at C$0.16.

The company reported C($0.08) EPS for the quarter, missing analysts’ consensus estimates of C($0.05) by C($0.03). The business had revenue of C$14.13 million during the quarter, compared to analysts’ expectations of C$15.50 million.

Valeo Pharma Stock Down 29.0 %

The company has a market cap of C$10.85 million, a PE ratio of -0.34 and a beta of 2.59. The company has a 50-day moving average of C$0.11 and a 200-day moving average of C$0.17.

Valeo Pharma Company Profile

Valeo Pharma Inc, a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma.